ArticleNature biotechnology2001
Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.
Article in Nature biotechnology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 79 citations in OpenAlex.
- Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein.Vaccines · 2023Article
- Article
- Targeting Head and Neck Cancer by Vaccination.Frontiers in immunology · 2018Review
- Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.Human vaccines & immunotherapeutics · 2017Article
- Article
- Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.Cancer immunology, immunotherapy : CII · 2015Review
- Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody.PloS one · 2015Article
- Trial watch: DNA vaccines for cancer therapy.Oncoimmunology · 2013Article
- Therapeutic cancer vaccines: past, present, and future.Advances in cancer research · 2013Review
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Frontiers in oncology · 2012Article
- DNA fusion vaccines enter the clinic.Cancer immunology, immunotherapy : CII · 2011Review
- Mechanisms of immunization against cancer using chimeric antigens.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Anti-idiotype antibodies in cancer treatment.Oncogene · 2007Review
- In planta production of two peptides of the Classical Swine Fever Virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X.BMC biotechnology · 2006Article
- Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.Immunology · 2006Article
- DNA vaccines for cancer too.Cancer immunology, immunotherapy : CII · 2006Review
- Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.Cancer immunology, immunotherapy : CII · 2005Article
- DNA vaccines to attack cancer.Proceedings of the National Academy of Sciences of the United States of America · 2004Review
- Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA delivery of tumor antigens can activate specific immune attack on cancer cells. However, antigens may be weak, and immune capacity can be compromised. Fusion of genes encoding activating sequences to the tumor antigen sequence facilitates promotion and manipulation of effector pathways. Idiotypic determinants of B-cell tumors, encoded by the variable region genes, are clone-specific tumor antigens. When assembled as single-chain Fv (scFv) alone in a DNA vaccine, immunogenicity is low. Previously, we found that fusion of a sequence from tetanus toxin (fragment C; FrC) promoted anti-idiotypic protection against lymphoma and myeloma. We have now investigated an alternative fusion gene derived from a plant virus, potato virus X coat protein, a primary antigen in humans. When fused to scFv, the self-aggregating protein generates protection against lymphoma and myeloma. In contrast to scFv-FrC, protection against lymphoma is mediated by CD4+ T cells, as is protection against myeloma. Plant viral proteins offer new opportunities to activate immunity against linked T-cell epitopes to attack cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.